Basiliximab
- Atc Codes:L04AC02
- CAS Codes:179045-86-4
- PHARMGKB ID:179045-86-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Simulect; Belgium: Simulect; Cyprus: Simulect; Czech Republic: Simulect; Denmark: Simulect; Estonia: Simulect; Finland: Simulect; France: Simulect; Germany: Simulect; Greece: Simulect; Hungary: Simulect; Ireland: Simulect; Italy: Simulect; Latvia: Simulect; Lithuania: Simulect; Luxembourg: Simulect; Malta: Simulect; Netherlands: Simulect; Poland: Simulect; Portugal: Simulect; Romania: Simulect; Slovakia: Simulect; Slovenia: Simulect; Spain: Simulect; Sweden: Simulect; UK: Simulect.
North America
Canada: Simulect; USA: Simulect.
Latin America
Argentina: Simulect; Brazil: Simulect; Mexico: Simulect.
Asia
Japan: Simulect.
Drug combinations
Chemistry
Basiliximab: (1) Immunoglobulin G~1~, anti-(human interleukin 2 receptor)(human-mouse monoclonal CHI621 γ1-chain), disulfide with human-mouse monoclonal CHI621 light chain, dimer; (2) Immunoglobulin G~1~ (human-mouse monoclonal CHI621 heavy chain antihuman interleukin 2 receptor), disulfide with human-mouse monoclonal CHI621 light chain, dimer. CAS-179045-86-4 (1998).
Pharmacologic Category
Immunosuppressive Agents; Monoclonal Antibody. (ATC-Code: L04AC02).
Mechanism of action
Blocks the α-chain of the interleukin-2 (IL-2) receptor complex expressed on activated T lymphocytes.
Therapeutic use
Prophylaxis of acute organ rejection in renal transplantation.
Pregnancy and lactiation implications
Use in pregnant women only when benefit exceeds potential risk to the fetus. Use not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to basiliximab, murine proteins, or any component of the formulation.
Warnings and precautions
Severe hypersensitivity reactions may occur (within 24 hours). Human antimurine antibodies may be developed. The incidences of lymphoproliferative disorders or opportunistic infections may be increased. Should be used as a component of immunosuppressive regimen (including cyclosporine and corticosteroids).